Abel Noser Solutions Introduces Industry’s First Comprehensive Options TCA Tool
New TCA-Powered Options Analytics Expected to Be a Valuable Addition for Global Equity Investors and Brokers
New York, NY, June 21, 2022 (GLOBE NEWSWIRE) -- Abel Noser Solutions today announced the launch of a first-of-its-kind options TCA product that covers all options strategies from covered calls to complex spread strategies. The offering measures option spreads along with analytics that show implied volatility, percentage of open interest traded, outlier trades, trading routes, commissions paid and other related benchmarks. From the pioneer and leading provider of TCA and related services in equities, fixed income, FX, and futures, this offering complements the company’s existing suite of post-trade products and trade surveillance solutions and makes Abel Noser Solutions unique as an independent vendor of global, multi-asset trade analysis.
“Our options TCA tool enables our clients to quantify the transaction costs of options hedging, income and more speculative strategies. You can measure calls and puts, spreads, straddles, strangles, buy-writes, and more while evaluating broker performance metrics and execution quality,” remarked Peter Weiler, Co-CEO, Abel Noser. “By identifying outlier trades, then comparing individual trading costs to peer benchmarks, users can track market liquidity to better assess trade impact and directly measure against ticks and quotes from all global exchanges.”
“The post-trade historical analysis in our options TCA tool clarifies trading costs for actionable insight,” said Ted Morgan, Abel Noser’s Chief Operating Officer. “Detailed transactions in graphical format allow clients to clearly see volumes, interval VWAPS, TWAPS, and various strike prices and spreads while supporting multiple industry standard identifiers for security identification such as FIGI, ISIN, OCC, and OPRA. Furthermore, our options TCA product is incorporated within our centralized multi-asset Trade Zoom analytics portal.”
Referring to the tool’s wide-ranging capabilities, Brett MacLeod, who heads Abel Noser’s sell-side group, noted that “the offering can also help brokers satisfy their FINRA Rule 5310 obligations for a regular and rigorous review of the execution quality for a range of orders in all equity securities and standardized options.” Pointing out the offering’s multi-aspect functionality, “We think clients will appreciate that it is also integrated within our Compliance+ suite for comprehensive compliance oversight and SEC Rule 606 reporting.”
Using robust and detailed market data and a significant universe of data from clients who trade options, Abel Noser Solutions is poised to deliver the same level of superior technology, methodology and consultancy services that the institutional investor community has come to expect. From customized reporting to higher level executive summary views, the company’s options TCA offering provides unprecedented clarity into the cost of options trading, best execution analysis and best practices.
About Abel Noser Solutions
Abel Noser Solutions has long been respected as a leader in the campaign to lower the costs associated with trading. With over 500 clients worldwide, the company offers multi-asset software products along with consultative and bespoke services in the areas of trade analytics, regulatory compliance, and trade surveillance. The firm continues to hold its place as the leading fintech innovator in TCA, compliance software, and service solutions. Learn more at www.abelnoser.com.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Huhtamaki publishes 2022 Half-yearly Report on July 21, 202230.6.2022 09:00:00 CEST | Press release
HUHTAMÄKI OYJ PRESS RELEASE 30.6.2022 AT 10:00 Huhtamaki publishes 2022 Half-yearly Reporton July21, 2022 Huhtamäki Oyj will publish its 2022 Half-yearly Report on Thursday, July 21, 2022, approximately at 8.30 am Finnish time (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors. Teleconference Huhtamaki will arrange a combined audiocast and teleconference on the same day at 9.30 am Finnish time, where the company’s management will present the results. The event will be followed by a Q&A session. The event will be held in English, it can be followed real-time at: https://huhtamaki.videosync.fi/2022-q2 If you wish to ask questions, please dial one of the following numbers 5-10 minutes prior to the call start: Finland Toll: +358981710310 Sweden Toll: +46 856642651 United Kingdom Toll: +44 3333000804 United States Toll: +1 6319131422 Confirmation code for the call is 23337170# An on-demand replay of the audiocast w
Fingerprints announces design win for its optical under-display solution with major Asian smartphone OEM30.6.2022 08:00:00 CEST | Press release
Fingerprint Cards AB (Fingerprints™) today announced that it has secured a design win* for its optical under-display solution, FPC 1632, with a major Asian smartphone OEM, following successful qualification tests earlier this year. We expect to commence shipments during the fourth quarter of 2022. “Since many years, Fingerprints is a well-established world leader in capacitive fingerprint sensors. The design win we are announcing today marks our entry into a new market segment: optical under-display fingerprint sensors. This will open up attractive new growth opportunities for us going forward, and our goal is to capture a significant share of this market,” says Ted Hansson, President Mobile, PC & Access China at Fingerprints. For more information about Fingerprints’ mobile device solutions, visit the website. * Fingerprints’ definition of Design Win (DW): The decision by a device vendor (OEM or ODM) to start development of one or several commercial product(s) incorporating Fingerprint
Inaugural Yara Clean Ammonia Capital Markets Day30.6.2022 08:00:00 CEST | Press release
Oslo, 30 June 2022: Today, Yara International ASA (“Yara”) will host a Capital Markets Day (“CMD”) for Yara Clean Ammonia (“YCA” or the “Company”). During the event, members of YCA’s management team will present key features of the Company, including its strategy and growth ambitions, as well as financial parameters and targets for the future. In May 2022, Yara announced that it is evaluating a potential initial public offering (“IPO”) of YCA on the Oslo Stock Exchange. “While the decision to list YCA will be made in due course, Yara is now excited to host an inaugural CMD for YCA to showcase their exciting story,” said Svein Tore Holsether, CEO and President of Yara. “YCA combines a leading midstream business with exceptional growth prospects and a value creating project portfolio.” Key highlights: Clean ammonia represents a massive opportunity that is projected to drive exponential, long-term market growth .YCA comprises existing cash flows from a market leading position  in a
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma30.6.2022 08:00:00 CEST | Press release
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 monthsStudy provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces the completed recruitment of 154 patients in the INITIUM trial. INITIUM is Ultimovacs’ Phase II clinical trial of its universal cancer vaccine UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab in metastatic malignant melanoma. Consistent with INITIUM’s event-driven design, topline progression-free survival results will be disclosed after progression of cancer or death has been observed in a total of 70 patients. “It is a remarkable achievement that Ultimovacs and its clinical partners have completed recruitment to INITIUM largely on schedule despite challenges caused by the pandemic,” said Carlos de Sou
Sampo plc’s share buybacks 29/06/202230.6.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 30/06/2022 at 08:30 am Sampo plc’s share buybacks 29/06/2022 On 29/06/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,37741.79AQEU49,88741.79CEUX8,78241.76TQEX102,19541.79XHELTOTAL175,24141.79 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 2,017,160 Sampo A shares representing 0.38 per cent of the total number of shares in Sampo plc. Details of e